Arcutis Biotherapeutics (ARQT) Enterprise Value (2020 - 2026)

Arcutis Biotherapeutics' Enterprise Value history runs 8 years deep, the most recent figure standing at -$189.5 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 30.18% year-over-year to -$189.5 million; the TTM figure through Mar 2026 stood at -$189.5 million (down 30.18% YoY), while the FY2025 annual figure was -$221.0 million, up 3.06% from the prior year.
• Enterprise Value for Q1 2026 stood at -$189.5 million, up from -$221.0 million in the prior quarter.
• The five-year high for Enterprise Value was -$118.4 million in Q2 2025, with the low at -$396.7 million in Q3 2022.
• The 5-year median for Enterprise Value is -$221.0 million (2025), against an average of -$232.3 million.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value soared 69.61% in 2023, then tumbled 174.23% in 2024.
• Arcutis Biotherapeutics' Enterprise Value stood at -$357.2 million in 2022, then soared by 48.38% to -$184.4 million in 2023, then declined by 23.63% to -$228.0 million in 2024, then rose by 3.06% to -$221.0 million in 2025, then grew by 14.23% to -$189.5 million in 2026.
• Business Quant data shows ARQT's Enterprise Value at -$189.5 million in Q1 2026, -$221.0 million in Q4 2025, and -$191.1 million in Q3 2025.